The University of Southern California (USC) was awarded a $915,936 Project Grant from the U.S. Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research to investigate SETD2 deficiency as a therapeutic target to upregulate viral mimicry for treating aggressive clear cell renal cell carcinoma in patients. This award is part of the program's focus on cancer, neurological disorders, and other health conditions affecting service members and veterans.
USC is collaborating with Cedars-Sinai Medical Center, a non-profit hospital and academic medical center, on a $526,769 sub-award to provide specialized research services, data analysis, and subject matter expertise for this cancer research project. The overall goal is to develop innovative treatments and advance scientific understanding to address critical military medical needs.